CDEK
← All organizations

Larimar Therapeutics

For profitWebsite ↗

Also known as: Chondrial Therapeutics, Inc. | Larimar Therapeutics, Inc.

Phase 1Phase 2Phase 3Phase 4

First clinical trial

Nov 30, 2019

Last known activity

Nov 30, 2024

Acquired by Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. → Larimar Therapeutics → Zafgen, Inc. on Dec 19, 2019

Timeline

2010s

  1. Jan 1, 2016

    Larimar Therapeutics— Founded

  2. Dec 19, 2019

    Zafgen, Inc.— Acquired By

  3. Dec 19, 2019

    Zafgen, Inc.— Now

2020s

  1. May 15, 2020

    Zafgen, Inc.— Acquired

Drugs by trial phase (4 distinct, 14 trials)

Phase 3 (0 own, 1 via acquisition)

Phase 2 (0 own, 2 via acquisition)

Phase 1 (0 own, 1 via acquisition)

Indications

Studied for

Subsidiaries (1 direct, 25 total across the full acquisition tree)

Recent trials (7)

Details

Founded
Bala-Cynwyd, PA, US Jan 1, 2016
Last known activity
Nov 30, 2024